We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:
Medicine & public health

Search Results

Showing 1-20 of 1,285 results

  1. Exploration of the influence of GOLGA8B on prostate cancer progression and the resistance of castration-resistant prostate cancer to cabazitaxel

    Castration-resistant prostate cancer (CRPC) represents the final stage of prostate cancer (PCa). Cabazitaxel, a taxane chemotherapy drug, is used in...

    Haopeng Li, **n’an Wang, ... ** Chen in Discover Oncology
    Article Open access 10 May 2024

  2. Pretreatment of prostate cancer cells with salinomycin and Wnt inhibitor increases the efficacy of cabazitaxel by inducing apoptosis and decreasing cancer stem cells

    Cancer stem cells (CSCs) are associated with metastasis and recurrence in prostate cancer as well as other cancers. We aimed to enhance the...

    Riza Serttas, Suat Erdogan in Medical Oncology
    Article 01 June 2023

  3. Cabazitaxel

    in Reactions Weekly
    Article 28 October 2023

  4. Cabazitaxel

    in Reactions Weekly
    Article 08 April 2023

  5. Cabazitaxel/enzalutamide

    in Reactions Weekly
    Article 16 September 2023

  6. Cabazitaxel

    in Reactions Weekly
    Article 25 March 2023

  10. Cabazitaxel

    in Reactions Weekly
    Article 03 December 2022

  13. Cabazitaxel/docetaxel

    in Reactions Weekly
    Article 17 September 2022

  14. An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective

    Background

    Cabazitaxel significantly improves clinical outcomes compared with a second androgen receptor-targeted agent (ARTA) in patients with...

    Alicia K. Morgans, Thomas Hutson, ... Nicholas J. Vogelzang in BMC Health Services Research
    Article Open access 14 July 2022

  15. Cabazitaxel/docetaxel

    in Reactions Weekly
    Article 29 January 2022

  16. Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel

    Background

    Cabazitaxel improves overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients progressing after docetaxel....

    Giorgia Gurioli, Vincenza Conteduca, ... Ugo De Giorgi in BMC Medicine
    Article Open access 31 January 2022

  17. Influence of Darolutamide on Cabazitaxel Systemic Exposure

    Stefan A. J. Buck, Niels A. D. Guchelaar, ... Ron H. J. Mathijssen in Clinical Pharmacokinetics
    Article 27 July 2022

  18. Cabazitaxel

    in Reactions Weekly
    Article 23 October 2021

  19. Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer

    Background

    In this study, we investigated the association between the early response of serum and hematological variables and the outcome of...

    Motohiro Fujiwara, Takeshi Yuasa, ... Junji Yonese in Cancer Chemotherapy and Pharmacology
    Article 10 June 2021

  20. Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents

    Background

    Cabazitaxel has played an important role in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC);...

    Hideaki Miyake, Ryo Sato, ... Atsushi Otsuka in International Journal of Clinical Oncology
    Article 13 July 2021
Did you find what you were looking for? Share feedback.